| Patents for C07K 16 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies (149,320) |
|---|
| 03/31/2011 | US20110076300 Hybrid Polypeptides Including Meningococcal fHBP Sequences |
| 03/31/2011 | US20110076286 Methods of inhibiting unwanted cell proliferation using hedgehog antagonists |
| 03/31/2011 | US20110076284 Novel Modulators |
| 03/31/2011 | US20110076283 Method for predicting and diagnosing brain tumor |
| 03/31/2011 | US20110076279 Fully human anti-vegf antibodies and methods of using |
| 03/31/2011 | US20110076275 Method of Modifying Isoelectric Point of Antibody Via Amino Acid Substitution in CDR |
| 03/31/2011 | US20110076270 Therapeutic Binding Molecules |
| 03/31/2011 | US20110076268 Antibodies against human respiratory syncytial virus (RSV) and methods of use |
| 03/31/2011 | US20110076267 Humanized antibody compositions and methods for binding lysophosphatidic acid |
| 03/31/2011 | US20110076265 Monoclonal antibodies having homosubtype cross-neutralization properties against influenza a viruses subtype h1 |
| 03/31/2011 | US20110076264 Immunoglobulin cleavage fragments as disease indicators and compositions for detecting and binding such |
| 03/31/2011 | US20110076263 Endoglin Antibodies |
| 03/31/2011 | US20110076262 Humanized anti-fgf19 antagonists and methods using same |
| 03/31/2011 | US20110076232 Specific binding proteins and uses thereof |
| 03/31/2011 | CA2775159A1 Method of acquiring proteins with high affinity by computer aided design |
| 03/31/2011 | CA2774836A1 Antagonists of dsg2 for treatment of cancer |
| 03/31/2011 | CA2774636A1 Neutralizing antibodies to hiv-1 and their use |
| 03/31/2011 | CA2773286A1 Disulfide stabilised multivalent antibodies |
| 03/31/2011 | CA2773240A1 Process for producing molecules containing specialized glycan structures |
| 03/31/2011 | CA2773099A1 Novel modulators |
| 03/31/2011 | CA2772230A1 Humanized antibodies specific for amino acid sequence rgd of an extracellular matrix protein and the uses thereof |
| 03/30/2011 | EP2302390A1 Methods for detecting and analyzing n-glycolylneuraminic acid (Neu5Gc) specific antibodies in biological materials |
| 03/30/2011 | EP2302383A2 Docetaxel conjugates and immunogens for use in an immunoassay |
| 03/30/2011 | EP2302382A2 Docetaxel conjugates and immunogens for use in an immunoassay |
| 03/30/2011 | EP2302041A1 Nucleic acid and corresponding protein entitled 161P2F10B useful in treatment and detection of cancer |
| 03/30/2011 | EP2301971A1 Antibodies that bind both BCMA and TACI |
| 03/30/2011 | EP2301970A1 Human antibodies that bind human IL-12 and methods for producing |
| 03/30/2011 | EP2301969A1 IL-31 monoclonal antibodies and methods of use |
| 03/30/2011 | EP2301968A2 Humanized monoclonal antibody HPAM4 |
| 03/30/2011 | EP2301967A2 Single domain antibodies for nasal administration |
| 03/30/2011 | EP2301966A1 Immunoglobulin variants and uses thereof |
| 03/30/2011 | EP2301965A1 Antibodies that bind cell-associated CA 125/0722P and methods of use thereof |
| 03/30/2011 | EP2301959A2 Motif-grafted hybrid polypeptides and uses thereof |
| 03/30/2011 | EP2301629A2 Anti-interferon-alpha antibodies |
| 03/30/2011 | EP2301581A1 Production and use of novel peptide-based agents for use with B1-specific antibodies |
| 03/30/2011 | EP2301580A1 Anti-VEGF antibodies |
| 03/30/2011 | EP2301579A1 Therapeutic method for reducing angiogenesis |
| 03/30/2011 | EP2301578A2 Methods for treating TWEAK-related conditions |
| 03/30/2011 | EP2301577A2 Methods for treating TWEAK-related conditions |
| 03/30/2011 | EP2301576A1 Therapeutic use of Anti-CS1 Antibodies |
| 03/30/2011 | EP2301575A1 Methods of therapy for solid tumors expressing the CD40 cell-surface antigen |
| 03/30/2011 | EP2301568A1 Antibody against IRTA2 for the treatment of tumour of hematopoietic origin |
| 03/30/2011 | EP2301535A1 Immunological uses of immunomodulatory compounds for vaccine and anti-infectious disease therapy |
| 03/30/2011 | EP2300825A1 P/gf-1 companion diagnostic methods and products |
| 03/30/2011 | EP2300500A1 Anti-flt3 antibodies |
| 03/30/2011 | EP2300499A1 Anti-prion protein antibody fragment |
| 03/30/2011 | EP2300498A2 Constructs and libraries comprising antibody surrogate kappa light chain sequences |
| 03/30/2011 | EP2300052A1 Novel synergistic effects |
| 03/30/2011 | EP2126049B1 Antibodies against human cytomegalovirus (hcmv) |
| 03/30/2011 | EP2027156B9 Hepatocyte growth factor (hgf) binding proteins |
| 03/30/2011 | EP1861424B1 Human monoclonal antibodies against hendra and nipah viruses |
| 03/30/2011 | EP1500698B1 Cell with depression or deletion of the activity of protein participating in gdp-fucose transport |
| 03/30/2011 | EP1426764B1 Method of diagnosing or monitoring saccharometabolic error |
| 03/30/2011 | EP1394261B1 Antigens for immunisation |
| 03/30/2011 | EP1317485B1 Myostatin antagonists and uses thereof |
| 03/30/2011 | CN1780855B Human il-1 beta antagonists |
| 03/30/2011 | CN1717418B Antibody for the thyrotropin receptor and uses thereof |
| 03/30/2011 | CN101998966A Methods of using cadherin 11 (CDH11) antagonists |
| 03/30/2011 | CN101995468A Time resolution immunoassay test kit and method of ciprofloxacin residual |
| 03/30/2011 | CN101995463A Composition for detecting rheumatoid arthritis immune antibody by dot immuno-gold filtration assay |
| 03/30/2011 | CN101995460A Ractopamine residual time resolution immunoassay kit and detection method thereof |
| 03/30/2011 | CN101993856A Duck-origin coronavirus ZZ2004-resisting monoclonal antibody, hybridoma cell strain and application thereof |
| 03/30/2011 | CN101993855A Hybridoma cell line 1C11 and anti-aflatoxin general monoclonal antibody generated by same as well as applications thereof |
| 03/30/2011 | CN101993493A Anti-tumor monoclonal antibody and preparation method and application thereof |
| 03/30/2011 | CN101993492A ScFv antibody for resisting H5N1 type highly-pathogenic avian influenza and application thereof |
| 03/30/2011 | CN101993491A Antibody combined with tubercle bacillus bacteriophage head protein as well as preparation method and application thereof |
| 03/30/2011 | CN101993490A Antibody combined with tubercle bacillus bacteriophage tail protein as well as preparation method and application thereof |
| 03/30/2011 | CN101519650B Gobrocypris rarus vitellogenin monoclonal antibody and application thereof |
| 03/30/2011 | CN101294162B P156 antigens for the immunodiagnosis of canine and human ehrlichioses and uses thereof |
| 03/30/2011 | CN101085811B SARS coronavirus pharmaceutical target and application thereof |
| 03/29/2011 | US7915396 Nucleic acid molecules encoding minimally immunogenic variants of SDR-grafted humanized antibody CC49 |
| 03/29/2011 | US7915395 Plasmid coding immunogenic fusion protein for use as drug delivery tool; antiproliferative agents; genetic vaccines |
| 03/29/2011 | US7915391 Humanized c-Kit antibody |
| 03/29/2011 | US7915390 Anti-Notch3 agonist antibodies and their use in the treatment of Notch3-related diseases |
| 03/29/2011 | US7915389 Anti-acharan sulfate antibody and its application |
| 03/29/2011 | US7915387 For directly inducing cell death without immune effector cells; antigens |
| 03/29/2011 | US7915380 Compositions, systems and methods for the diagnosis, prevention and treatment of disorders associated with azetidine-2-carboxylic acid |
| 03/29/2011 | US7915052 Immunoglobulin peptides against heated bovine blood |
| 03/29/2011 | US7915041 Hybridoma capable of producing anti-dectin-1 monoclonal antibody |
| 03/29/2011 | US7915009 Modulating NF-kappa B by administering antigens or polynucleotide encoding antigens, antibody; treating cancer, tumor, Alzheimer's disease or a spongiform encephalopathy; DNA vaccine in kits |
| 03/29/2011 | US7915004 Monoclonal antibodies, hybridomas, improved method for determining the protein PTX3 and kit for said determination |
| 03/29/2011 | US7915001 Detection of specific nitrated markers |
| 03/29/2011 | US7914795 Moraxella catarrhalis outer membrane protein-106 polypeptide, gene sequence and uses thereof |
| 03/29/2011 | US7914794 Protein vaccine; culture product; genetic engineering |
| 03/29/2011 | US7914792 Methods and compounds for raising antibodies and for screening antibody repertoires |
| 03/29/2011 | US7914790 Human IgM antibody lysing activated lymphocytes under mediation by homologous complement |
| 03/29/2011 | US7914787 Provide inter alia a bi-specific antibody or antibody fragment having one arm that specifically binds a targeted tissue and one other arm that specifically binds a targetable conjugate that can be modified for use in a wide variety of diagnostic and therapeutic applications |
| 03/29/2011 | US7914784 Insulin-like growth factor I receptor (IGF-IR) specific monoclonal antibodies for diagnosis, prevention and treatment of cell proliferative disorders |
| 03/29/2011 | US7914780 Aminopeptidase A (APA) targeting peptides for the treatment of cancer |
| 03/29/2011 | US7914778 Methods of treatment using IL-16 antagonist peptides |
| 03/29/2011 | CA2617341C Methods of vaccine administration, new feline caliciviruses, and treatments for immunizing animals against feline paraovirus and feline herpes virus |
| 03/29/2011 | CA2522378C Method of detecting probnp with a monoclonal antibody binding to the amino acids 41-46 |
| 03/29/2011 | CA2489475C A method for simultaneous production of multiple proteins; vectors and cells for use therein |
| 03/29/2011 | CA2418784C Use of compounds derived from the genus euphorbia for the treatment of carcinoma of the bladder |
| 03/29/2011 | CA2390652C Human circulating virus-inhibiting peptide (virip) and its use |
| 03/29/2011 | CA2345276C Flt4 (vegfr-3) as a target for tumor imaging and anti-tumor therapy |
| 03/29/2011 | CA2263798C G-coupled receptor showing selective affinity for atp |
| 03/29/2011 | CA2256306C Antibodies against a complex of cd4 and a chemokine receptor domain, and their use against hiv infections |
| 03/29/2011 | CA2252438C Histidine-tagged intimin and methods of using intimin to stimulate an immune response and as an antigen carrier with targeting capability |
| 03/29/2011 | CA2239151C Integrin-linked kinase, its inhibitors and methods of medical treatment using these inhibitors, gene therapy and pseudo-substrate inhibitors |